Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. 2019 08 01; 134(5):421-431.
View in:
PubMed
subject areas
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
Antineoplastic Combined Chemotherapy Protocols
Dexamethasone
Drug Resistance, Neoplasm
Female
Humans
Male
Middle Aged
Multiple Myeloma
Oligopeptides
Prognosis
Recurrence
Retreatment
Survival Analysis
Treatment Outcome
authors with profiles
Andrzej Jakubowiak